KEAP1 and lung cancer: The hypermethylation of CpG islands catalyzed by DNA methyltransferases (DNMTs) in the promoters of KEAP1 inhibited its transcriptional activity and led to the accumulation of NRF2, which conferred growth advantages and therapeutic resistance to many cancers, such as glioma, colorectal cancer (CRC), and lung cancer [73,74,75].